Down 32% in 2026, Is Symbotic Stock a Buy? | SYM Stock Analysis
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 27 Aug 2026, 12:45 UTC
- Recorded by Tahlil Plus
- 27 Aug 2026, 13:56 UTC
AI-generated source summary
Symbiotic's revenue has shown a consistent upward trend over the past decade, reaching $2.648 billion in the trailing twelve months. The company's operating margin has also improved significantly, moving from -35% to 1.43% over the last few years. Despite a late start in online sales, Symbiotic is capturing market share and improving its operational efficiency. Its returns on invested capital have recovered from a low point to approximately 7% in the most recent update. The company's beta of 1.96 suggests it is more volatile than the overall market. Based on a discounted cash flow analysis, the intrinsic value per share is estimated at $51.74, while the current market price is $40.95, indicating potential upside.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.